<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35819713</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.</ArticleTitle><Pagination><StartPage>1180</StartPage><EndPage>1192</EndPage><MedlinePgn>1180-1192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01271-2</ELocationID><Abstract><AbstractText>Thoughtful clinical trial design is critical for efficient therapeutic development, particularly in the field of amyotrophic lateral sclerosis (ALS), where trials often aim to detect modest treatment effects among a population with heterogeneous disease progression. Appropriate outcome measure selection is necessary for trials to provide decisive and informative results. Investigators must consider the outcome measure's reliability, responsiveness to detect change when change has actually occurred, clinical relevance, and psychometric performance. ALS clinical trials can also be performed more efficiently by utilizing statistical enrichment techniques. Innovations in ALS prediction models allow for selection of participants with less heterogeneity in disease progression rates without requiring a lead-in period, or participants can be stratified according to predicted progression. Statistical enrichment can reduce the needed sample size and improve study power, but investigators must find a balance between optimizing statistical efficiency and retaining generalizability of study findings to the broader ALS population. Additional progress is still needed for biomarker development and validation to confirm target engagement in ALS treatment trials. Selection of an appropriate biofluid biomarker depends on the treatment mechanism of interest, and biomarker studies should be incorporated into early phase trials. Inclusion of patients with ALS as advisors and advocates can strengthen clinical trial design and study retention, but more engagement efforts are needed to improve diversity and equity in ALS research studies. Another challenge for ALS therapeutic development is identifying ways to respect patient autonomy and improve access to experimental treatment, something that is strongly desired by many patients with ALS and ALS advocacy organizations. Expanded access programs that run concurrently to well-designed and adequately powered randomized controlled trials may provide an opportunity to broaden access to promising therapeutics without compromising scientific integrity or rushing regulatory approval of therapies without adequate proof of efficacy.</AbstractText><CopyrightInformation>&#xa9; 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0002-1561-2419</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA, USA. cfourni@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs, Atlanta, GA, USA. cfourni@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Outcome measures</Keyword><Keyword MajorTopicYN="N">Prediction models</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35819713</ArticleId><ArticleId IdType="pmc">PMC9275386</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01271-2</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01271-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hergesheimer R, et al. Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2020;21(9):1103&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">32242755</ArticleId></ArticleIdList></Reference><Reference><Citation>Katyal N, Govindarajan R. Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol. 2017;8:521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626834</ArticleId><ArticleId IdType="pubmed">29033893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmaier SL, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781297</ArticleId><ArticleId IdType="pubmed">35062955</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5(4):474&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):480&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, Dimachkie MM, Agbas A. Blood-based biomarkers for amyotrophic laerosis. In Amyotrophic Lateral Sclerosis, T. Araki, Editor. Brisbane (AU); 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34473438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann Clin Transl Neurol. 2020;7(7):1148&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="pubmed">32515889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R, et al. ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3&#x2013;4):216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">32458763</ArticleId></ArticleIdList></Reference><Reference><Citation>U.K.-L.S. Group et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornese P, et al. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosur Psychiatry. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35228271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009;66(6):758&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">19506136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19) Muscle Nerve. 2020;61(2):218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>PCNS Advisory Committee. Combined FDA and Applicant Briefing Document, NDA# 216660, Drug Name: AMX0035/ sodium phenylbutyrate (PB) and taurursodiol (TURSO), U.S. Food and Drug Administration. 2022. https://www.fda.gov/media/157186/download. Accessed June 2022.</Citation></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, et al. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):50&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036426</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes J, et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology. 2006;67(7):1294&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030772</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano B, et al. Inter-evaluator reliability of the ALS functional rating scale. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799553</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. Natural history of ALS: symptoms, strength, pulmonary function, and disability. Neurology. 1996;47(4 Suppl 2):S71&#x2013;S82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858055</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, et al. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, et al. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, et al. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):178&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N, et al. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study. Acta Neurol Belg. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35034333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, et al. How common are ALS plateaus and reversals? Neurology. 2016;86(9):808&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>The Writing Group. A.L.S.S.G. Edaravone Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency Withdrawal Assessment Report, Radicava, EMA. 2019. https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-radicava_en.pd. Accessed July 2022.</Citation></Reference><Reference><Citation>Berry JD, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, et al. Development and validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale (roads). JAMA Neurol. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, et al. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale. Eur J Neurol. 2021;28(6):1876&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pubmed">33686758</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U, et al. Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2021;1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34894916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed N, Baker MR, Bashford J. The landscape of neurophysiological outcome measures in ALS interventional trials: a systematic review. Clin Neurophysiol. 2022;137:132&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10166714</ArticleId><ArticleId IdType="pubmed">35313253</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011;77(3):235&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136054</ArticleId><ArticleId IdType="pubmed">21676915</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, et al. Motor unit number index (MUNIX): a novel neurophysiological technique to follow disease progression in amyotrophic lateral sclerosis. Muscle Nerve. 2010;42(3):379&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">20589888</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekestein WA, et al. Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): a direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol. 2012;123(8):1644&#x2013;1649.</Citation><ArticleIdList><ArticleId IdType="pubmed">22321299</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, et al. Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres. Clin Neurophysiol. 2018;129(8):1756&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803404</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve. 2004;30(4):463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15316983</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. Motor unit number estimation (MUNE): where are we now? Clin Neurophysiol. 2018;129(8):1507&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">29804042</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Electrical impedance myography: background, current state, and future directions. Muscle Nerve. 2009;40(6):936&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824130</ArticleId><ArticleId IdType="pubmed">19768754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13(5):439&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422377</ArticleId><ArticleId IdType="pubmed">22670883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanz O, et al. Cortical hyperexcitability in patients with C9ORF72 mutations: relationship to phenotype. Muscle Nerve. 2016;54(2):264&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940214</ArticleId><ArticleId IdType="pubmed">26799151</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2015;126(4):803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227219</ArticleId></ArticleIdList></Reference><Reference><Citation>Chervyakov AV, et al. Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve. 2015;51(1):125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">25049055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87(6):617&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, et al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56(4):710&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">28120413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakers JNE, et al. Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease. J Neurol. 2021;268(5):1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068646</ArticleId><ArticleId IdType="pubmed">33355879</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Pulmonary function decline in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(sup1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">34348540</ArticleId></ArticleIdList></Reference><Reference><Citation>Enache I, et al. Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7&#x2013;8):511&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">28728441</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, et al. Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol. 2020;267(6):1615&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">32052165</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Mozaffar T. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opin Investig Drugs. 2014;23(11):1541&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">24965719</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond) 2014;4(7):605&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305182</ArticleId><ArticleId IdType="pubmed">28203356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabor-Gray LC, et al. Characteristics of impaired voluntary cough function in individuals with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1&#x2013;2):37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513719</ArticleId><ArticleId IdType="pubmed">30652513</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al.&#xa0;A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener.&#xa0;2019;1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">31081694</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. Respiratory function tests in amyotrophic lateral sclerosis: the role of maximal voluntary ventilation. J Neurol Sci. 2022;434:120143.</Citation><ArticleIdList><ArticleId IdType="pubmed">35030382</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7&#x2013;8):528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">28741375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, et al. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2013;6):321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29566571</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with aLS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):287&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, et al. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, et al. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: challenges and opportunities. Muscle Nerve. 2020;62(2):182&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283687</ArticleId><ArticleId IdType="pubmed">32445195</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleman J, et al. Home-monitoring of vital capacity in people with a motor neuron disease. J Neurol. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9217878</ArticleId><ArticleId IdType="pubmed">35129626</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann GM, et al. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. NPJ Digit Med. 2020;3:132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555482</ArticleId><ArticleId IdType="pubmed">33083567</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gancedo L, et al. Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth. 2019;7(12):e13433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942190</ArticleId><ArticleId IdType="pubmed">31859676</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukenhorst AL, et al. Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS. Muscle Nerve. 2021;63(2):258&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898508</ArticleId><ArticleId IdType="pubmed">33118628</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat Neurosci. 2022;25(2):226&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuffner R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33(1):51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N, Manser P. Does including machine learning predictions in ALS clinical trial analysis improve statistical power? Ann Clin Transl Neurol. 2020;7(10):1756&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545604</ArticleId><ArticleId IdType="pubmed">32862509</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu D, et al. Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(sup1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">34348539</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3(11):866&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, et al. A permutation test for assessing the presence of individual differences in treatment effects. Stat Methods Med Res. 2021;30(11):2369&#x2013;2381.</Citation><ArticleIdList><ArticleId IdType="pubmed">34570622</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, et al. Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1&#x2013;2):49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">34251911</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9540225</ArticleId><ArticleId IdType="pubmed">35508892</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen DRT, Paludan-Muller AS, Hrobjartsson A. Randomized clinical trials with run-in periods: frequency, characteristics and reporting. Clin Epidemiol. 2019;11:169&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377048</ArticleId><ArticleId IdType="pubmed">30809104</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Is edaravone harmful? (A placebo is not a control) Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):477&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">30373406</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Fournier CN. Unintended consequences of approving unproven treatments-hope, hype, or harm? JAMA Neurol. 2022;79(2):117&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">35006259</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7&#x2013;8):471&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. Ann Neurol. 2022;91(2):165&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">34935174</ArticleId></ArticleIdList></Reference><Reference><Citation>Adaptive Platform Trials Coalition Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462747</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander BM, et al. individualized screening trial of innovative glioblastoma therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. JCO Precis Oncol. 2019;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448806</ArticleId><ArticleId IdType="pubmed">32914038</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2022;93(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74(5):525&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18(5&#x2013;6):397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">28631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, et al. Biomarkers in motor neuron disease: a state of the art review. Frontiers in Neurol. 2019;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(12):e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher NR, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S, Atassi N. Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6405430</ArticleId><ArticleId IdType="pubmed">30881332</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, et al. Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014&#x2013;2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35023792</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand D, et al. Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic. Neurology. 2021;96(6):e840&#x2013;e844.</Citation><ArticleIdList><ArticleId IdType="pubmed">33372030</ArticleId></ArticleIdList></Reference><Reference><Citation>Le D, et al. Improving African American women's engagement in clinical research: a systematic review of barriers to participation in clinical trials. J Natl Med Assoc. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189005</ArticleId><ArticleId IdType="pubmed">35279325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, et al. Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663902</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Drug Evaluation and Research. Guidance Document: Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry, U.S. Food and Drug Administration. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry. Accessed June 2022.</Citation></Reference><Reference><Citation>Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: consensus and opportunities for alignment. Neurology. 2019;93(2):66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Right-to-try investigational therapies for incurable disorders. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1451&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968371</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer K, Bedlack RS. Diaphragm pacing in amyotrophic lateral sclerosis: a literature review. Muscle Nerve. 2012;46(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692995</ArticleId></ArticleIdList></Reference><Reference><Citation>Onders RP, et al. Complete worldwide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients. Surg Endosc. 2009;23(7):1433&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067067</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiesing CA, et al. Laparoscopic diaphragmatic pacer placement&#x2014;a potential new treatment for ALS patients: a brief description of the device and anesthetic issues. J Clin Anesth. 2010;22(7):549&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">21056813</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Devices and Radiologic Health. Summary of Safety and Probably Benefit (SSPB): Diaphragm Pacing Stimulator,&#xa0; U.S. Food and Drug Administration. 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf10/H100006b.pdf. Accessed June 2022.</Citation></Reference><Reference><Citation>Amirjani N, et al. Is there a case for diaphragm pacing for amyotrophic lateral sclerosis patients? Amyotroph Lateral Scler. 2012;13(6):521&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">22632380</ArticleId></ArticleIdList></Reference><Reference><Citation>Di PWC, Di PSGC. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14(9):883&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">26234554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Bermejo J, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15(12):1217&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">27751553</ArticleId></ArticleIdList></Reference><Reference><Citation>H.R. 3537: accelerating access to critical therapies for ALS act.</Citation></Reference><Reference><Citation>Lacomblez L, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47(6 Suppl 4):S242&#x2013;S250.</Citation><ArticleIdList><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65(3):291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9305113</ArticleId><ArticleId IdType="pubmed">34890069</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">22415942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Glass JD. Modeling the course of amyotrophic lateral sclerosis. Nat Biotechnol. 2015;33(1):45&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">25574636</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>